Most Read

The company developed the highly selective BTK inhibitor orelabrutinib for the treatment of autoimmune diseases and cancers. InnoCare co-founder, chairwoman and CEO Dr Jasmine Cui said: “Orelabrutinib’s NDA

Expected to be funded using nearly $35m of cash and cash equivalents at closing, the combined company will focus on advancing CalciMedica’s pipeline of first-in-class product candidates. The

SDX is the company’s proprietary prodrug of d-methylphenidate (d-MPH) and is the sole active pharmaceutical ingredient (API) in its lead clinical candidate KP1077. KP1077 is being developed for

As per the terms of the agreement, Tenacia will get sole rights to develop and commercialise some formulations of ganaxolone in Mainland China, Hong Kong, Macau and Taiwan,

Curevo Vaccine CEO George Simeon said: “Completing this A1 round ahead of data from our Phase 2b trial of CRV-101 head-to-head against Shingrix is a meaningful demonstration of

The financing round was co-led by ORI Capital, Longitude Capital and Decheng Capital. It has also seen participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge

Nearly 1,600 people in England alone are expected to benefit from the immunotherapy drug. Previously, the drug was available for a small group of people with advanced TNBC

The new, oral formulation of CD/LD extended-release capsules, IPX203 features immediate-release granules and extended-release beads. Findings from the pivotal Phase III RISE-PD clinical trial showed that the extended-release

The collaboration will focus on discovering and developing nucleic acid-based immunotherapies for selected oncology targets using Harbour BioMed’s heavy chain only antibody discovery platform (HCAb). HCAb’s technology produces